Company Interview / Paradigm Biopharmaceuticals (ASX: PAR) Investor Presentation

Paradigm Biopharmaceuticals (ASX:PAR) is focused on a late-stage drug development programme targeting osteoarthritis, a condition affecting up to 15% of the population globally.

Rennie states that current osteoarthritis treatments, usually analgesics and anti-inflammatories, often fail to address worsening disease in moderate to severe cases which is why the company's phase three clinical trial is pivotal, offering an indication of the probability of the trial’s success. Paradigm has secured significant funding to reach these milestones, with $27 million ensuring runway through key phases, though further capital will be required post-interim analysis to drive commercialisation.

Paradigm’s drug, pentosan polysulfate sodium, aims not only to reduce pain and joint stiffness but also to slow underlying disease progression.

*The information contained in this event is general in nature and is not intended as advice. Before acting on information you've seen or heard at this event, you should seek professional financial advice that takes into account your personal circumstances. 

You should be aware that companies presenting do so under commercial agreement with AUSBIZ CAPITAL PTY LTD